Novel Screening methods to Prevent Osteoporosis
The technology provides methods to screen compounds that retain the anti-inflammatory properties of glucocorticoids yet do not result in bone loss or osteoporosis due to apoptosis of osteoblasts and osteocytes. This technology demonstrates that glucocorticoid administration increases apoptosis of mature osteoblasts and osteocytes and decreases bone formation rate and bone mineral density accompanied by defective osteoblastogenesis and osteoclastogenesis in the bone marrow.
Sector: Medical Technologies
Area of Application: Pharma industry, Medical industry
Keywords: prevent Osteoporosis, decreased bone formation
Advantages: Test compound (Glucocorticoid analog) reduces the bone deteriorating effects, while retaining the antiinflammatory properties of the glucocorticoid. The test compound stimulates bone development. The test compound increases bone mineral density. Test compound reduces the bone deteriorating effects of the glucocorticoid.
Environmental aspects: Not Applicable
Development Status: Laboratory Model
Legal Protection: Patent
Transfer Terms: Technology Licensing
Target Countries: India
Estimated cost (US$):
Upload any relevant document:
Contact Person: SkyQuest Technology Consulting Pvt. Ltd.
Address: 501, Krishna Complex, Opp. Devashish School, Bodakdev
Zip/Pin Code: 380054